Viking Thera (VKTX)

$34.42 +0.50 (1.47%)
Market Cap 3.81B
Revenue (ttm) 0.00
Net Income (ttm) -109.96M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 4,385,100
Avg Vol 6,990,936
Day's Range N/A - N/A
Shares Out 112.45M
Stochastic %K 60%
Beta 0.64
Analysts Strong Sell
Price Target $88.88

Company Profile

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It develops VK5211, an orally available non-steroidal selectiv...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 704 4660
Address:
9920 Pacific Heights Boulevard, Suite 350, San Diego, United States
MoneyGroupLLC
MoneyGroupLLC Oct. 25 at 6:27 AM
Enter: $VKTX Calls Strike Price: $35 Expiry Date: NOV 14 2025 Buy in Price: $2.70 - $4.60 Sell Price: $3.89 Profit : +44% (Turn every $1 into $1.44) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
DarkOrb
DarkOrb Oct. 25 at 3:40 AM
$VKTX Nothing is forcing BP to make a move. Their stock prices aren't suffering, VKTX stock price isn't running higher, etc. So they can wait for more trial data and more clarity on the obesity marketplace.
1 · Reply
JusKallmeGravy
JusKallmeGravy Oct. 25 at 2:12 AM
$VKTX We all have an opinion or two for what is best for Viking. The unfortunate truth is I pity the fool who gets it exactly right. The unfortunate soul who does will beat her, himself, or its self up for the rest of their life. For not becoming a billionaire if nothing else…not to mention the fact the SEC will be investigating the lucky winner guesser for the next 5 yrs . None the less - What we need is a ranking of the top 10 or 20 possibilities. We can adjust the rankings as things progress. Up or down …maybe Robinhood draft kings will let us take bets on the final 4 …or the eventual winner. I need some help tho…I’m full of ideas and only have two clumsy thumbs. Let’s get a form circulating At least the top ten …but I fear we could mis it completely if we don’t do a top 20 …any long shot can pull a rabbit out of … . Partnership or buy-out are the same value to keep it simple . We need a committee . I have done suggestions.
0 · Reply
saifnila2
saifnila2 Oct. 25 at 1:30 AM
$VKTX jpm actually lowered price to 75 from 80. Go figure. Absolutely nuts. No justification for price reduction, the analysts make this up from whatever they like. This has the potential for double digit billions revenue in a couple of years.
1 · Reply
biolover
biolover Oct. 25 at 1:26 AM
$VKTX the issue If BP understand phase 2 data and extrapolate to approval after all the dump predictions by novo and some analysts on CagriSema , MariTide , orforglipron….that were wrong. Probably as phase 3 trials progress and efficacy , safety leak .. more confidence grows. CEOs such as Bourla were more comfortable taking risk on a few billions. Here we talk about much more. Also Trump Lilly deal should settle uncertainty.
0 · Reply
lakeswim951
lakeswim951 Oct. 25 at 1:12 AM
$VKTX At this point, how can other big pharma companies not named Lilly and Nvo afford not to buy this company🤔
1 · Reply
biolover
biolover Oct. 25 at 12:52 AM
$VKTX clear correlation between SP rise from Sep 30 and the short coverage of 2 M. These shorted shares and daily massive trades by short acounts what is responsible for SP decline last 16 months. 2 M covered shares resulted in about 30% rise in SP ?
0 · Reply
RunGal
RunGal Oct. 25 at 12:46 AM
$VKTX Leerink buy rating…$118.
0 · Reply
FE123
FE123 Oct. 24 at 10:30 PM
$VKTX Short interest down over 2 Million because Deal is on the Way!!
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 24 at 10:14 PM
Enter: $VKTX NOV 14 2025 $35 CALLS Buy in Price: $2.76 - $2.95 Take Profit: $3.39 Stop Bleeding: $2.43 ROI Potential: 23% https://moneygroup.us/
0 · Reply
Latest News on VKTX
Viking Therapeutics Q3 Earnings: What We Learned (And Why We Should Keep Faith)

Oct 23, 2025, 10:42 AM EDT - 1 day ago

Viking Therapeutics Q3 Earnings: What We Learned (And Why We Should Keep Faith)

Viking Therapeutics: The Prime Target In The Obesity Gold Rush

Oct 23, 2025, 10:05 AM EDT - 1 day ago

Viking Therapeutics: The Prime Target In The Obesity Gold Rush

Viking Therapeutics, Inc. (VKTX) Q3 2025 Earnings Call Transcript

Oct 22, 2025, 7:33 PM EDT - 2 days ago

Viking Therapeutics, Inc. (VKTX) Q3 2025 Earnings Call Transcript

Viking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 22, 2025, 4:05 PM EDT - 2 days ago

Viking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Viking Therapeutics Announces Initiation of VK2735 Maintenance Dosing Clinical Trial in Patients with Obesity

Oct 21, 2025, 7:05 AM EDT - 3 days ago

Viking Therapeutics Announces Initiation of VK2735 Maintenance Dosing Clinical Trial in Patients with Obesity

Viking Therapeutics to Report Financial Results for Third Quarter 2025 on October 22, 2025

Oct 15, 2025, 4:05 PM EDT - 9 days ago

Viking Therapeutics to Report Financial Results for Third Quarter 2025 on October 22, 2025

Viking Therapeutics: A Speculative Buy

Oct 4, 2025, 9:44 AM EDT - 20 days ago

Viking Therapeutics: A Speculative Buy

Viking Therapeutics: Overdue For Gains

Sep 28, 2025, 2:00 PM EDT - 26 days ago

Viking Therapeutics: Overdue For Gains

Viking Therapeutics, Inc. (VKTX) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript

Sep 23, 2025, 1:53 PM EDT - 4 weeks ago

Viking Therapeutics, Inc. (VKTX) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript

Viking Therapeutics, Inc. (VKTX) Q4 2023 Earnings Call Transcript

Sep 22, 2025, 1:55 PM EDT - 4 weeks ago

Viking Therapeutics, Inc. (VKTX) Q4 2023 Earnings Call Transcript

Viking Therapeutics, Inc. (VKTX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 8, 2025, 5:43 PM EDT - 6 weeks ago

Viking Therapeutics, Inc. (VKTX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Viking Therapeutics to Participate at Upcoming Investor Conferences

Aug 28, 2025, 4:30 PM EDT - 2 months ago

Viking Therapeutics to Participate at Upcoming Investor Conferences

Viking: Still On Track, But The Compass Needs Recalibration

Aug 23, 2025, 6:57 AM EDT - 2 months ago

Viking: Still On Track, But The Compass Needs Recalibration

Viking Therapeutics: Panic Creates Opportunity

Aug 20, 2025, 8:52 PM EDT - 2 months ago

Viking Therapeutics: Panic Creates Opportunity

Viking Therapeutics: What's Happening With VKTX Stock?

Aug 20, 2025, 9:50 AM EDT - 2 months ago

Viking Therapeutics: What's Happening With VKTX Stock?

Why Viking Therapeutics stock reaction to obesity pill data is wildly ‘overdone'

Aug 19, 2025, 9:38 PM EDT - 2 months ago

Why Viking Therapeutics stock reaction to obesity pill data is wildly ‘overdone'

Mizuho's Jared Holz talks Viking Therapeutics' massive stock drop on obesity pill data

Aug 19, 2025, 6:27 PM EDT - 2 months ago

Mizuho's Jared Holz talks Viking Therapeutics' massive stock drop on obesity pill data

Viking Obesity Pill Faces Steep Climb Against Lilly's Tirzepatide, Analyst Calls Downtrend Reaction 'Extreme'

Aug 19, 2025, 2:44 PM EDT - 2 months ago

Viking Obesity Pill Faces Steep Climb Against Lilly's Tirzepatide, Analyst Calls Downtrend Reaction 'Extreme'

The market reaction is overdone on Viking Therapeutics, says BTIG's Justin Zelin

Aug 19, 2025, 1:45 PM EDT - 2 months ago

The market reaction is overdone on Viking Therapeutics, says BTIG's Justin Zelin

Viking Therapeutics plummets on new obesity drug data. Here's a breakdown

Aug 19, 2025, 12:19 PM EDT - 2 months ago

Viking Therapeutics plummets on new obesity drug data. Here's a breakdown

Viking Therapeutics Stock Plunges on Oral Weight-Loss Pill Study Results

Aug 19, 2025, 12:05 PM EDT - 2 months ago

Viking Therapeutics Stock Plunges on Oral Weight-Loss Pill Study Results

Viking Therapeutics: Wall Street Mistaken To Dump After Obesity Pill Study Success

Aug 19, 2025, 12:03 PM EDT - 2 months ago

Viking Therapeutics: Wall Street Mistaken To Dump After Obesity Pill Study Success

Viking Therapeutics Shares Nosedive Toward Worst Day Ever After Obesity Trial Data

Aug 19, 2025, 11:00 AM EDT - 2 months ago

Viking Therapeutics Shares Nosedive Toward Worst Day Ever After Obesity Trial Data

Viking Therapeutics shares fall more than 30% on disappointing obesity pill trial data

Aug 19, 2025, 9:39 AM EDT - 2 months ago

Viking Therapeutics shares fall more than 30% on disappointing obesity pill trial data

Like Eli Lilly, Viking Therapeutics' Oral Weight Loss Drug Disappoints, Stock Tanks

Aug 19, 2025, 9:28 AM EDT - 2 months ago

Like Eli Lilly, Viking Therapeutics' Oral Weight Loss Drug Disappoints, Stock Tanks

LLY

Viking Therapeutics' stock tumbles after results of oral weight-loss drug trial. It has company.

Aug 19, 2025, 9:11 AM EDT - 2 months ago

Viking Therapeutics' stock tumbles after results of oral weight-loss drug trial. It has company.

Viking Therapeutics stock tumbles 37% today, but here's why you should ‘HOLD'

Aug 19, 2025, 8:57 AM EDT - 2 months ago

Viking Therapeutics stock tumbles 37% today, but here's why you should ‘HOLD'

Viking Therapeutics' oral weight-loss pill meets expectations in mid-stage study

Aug 19, 2025, 7:18 AM EDT - 2 months ago

Viking Therapeutics' oral weight-loss pill meets expectations in mid-stage study

Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity

Aug 19, 2025, 7:08 AM EDT - 2 months ago

Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity

Viking Therapeutics: Still On Track

Aug 18, 2025, 8:56 PM EDT - 2 months ago

Viking Therapeutics: Still On Track

Viking Therapeutics Q2: Confidently Continuing The Recovery

Jul 25, 2025, 10:15 AM EDT - 3 months ago

Viking Therapeutics Q2: Confidently Continuing The Recovery

Viking Therapeutics, Inc. (VKTX) Q2 2025 Earnings Call Transcript

Jul 23, 2025, 9:45 PM EDT - 3 months ago

Viking Therapeutics, Inc. (VKTX) Q2 2025 Earnings Call Transcript

Viking Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 23, 2025, 4:05 PM EDT - 3 months ago

Viking Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Viking Therapeutics to Report Financial Results for Second Quarter 2025 on July 23, 2025

Jul 16, 2025, 4:05 PM EDT - 3 months ago

Viking Therapeutics to Report Financial Results for Second Quarter 2025 on July 23, 2025

Viking Therapeutics: What's Next After GLP-1 Hype Dies Down And Competition Intensifies

Jul 10, 2025, 9:30 AM EDT - 3 months ago

Viking Therapeutics: What's Next After GLP-1 Hype Dies Down And Competition Intensifies

Viking: I'm Bullish On Oral/Injectable GLP-1 Obesity Data Catalysts

Jul 3, 2025, 3:05 PM EDT - 4 months ago

Viking: I'm Bullish On Oral/Injectable GLP-1 Obesity Data Catalysts

What's Going On With Viking Therapeutics Stock On Wednesday?

Jun 25, 2025, 1:01 PM EDT - 4 months ago

What's Going On With Viking Therapeutics Stock On Wednesday?

Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735

Jun 25, 2025, 7:03 AM EDT - 4 months ago

Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735

Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz

Jun 23, 2025, 6:10 PM EDT - 4 months ago

Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz

AMGN GPCR LLY NVO PFE REGN XBI

Altimmune Vs. Viking Therapeutics: Evaluating Pipeline Maturity, And Takeover Potential

Jun 2, 2025, 10:51 AM EDT - 5 months ago

Altimmune Vs. Viking Therapeutics: Evaluating Pipeline Maturity, And Takeover Potential

ALT

Viking Therapeutics: Buy It For The Future And Ignore The Noise

May 27, 2025, 9:00 AM EDT - 5 months ago

Viking Therapeutics: Buy It For The Future And Ignore The Noise

Viking Therapeutics: Weight-Loss Story Remains Intact

May 22, 2025, 7:24 AM EDT - 5 months ago

Viking Therapeutics: Weight-Loss Story Remains Intact

Viking Therapeutics: A High Potential Biotech Play With Manageable Risks

May 20, 2025, 11:30 AM EDT - 5 months ago

Viking Therapeutics: A High Potential Biotech Play With Manageable Risks

Viking Therapeutics: Near-Term Catalysts And Competitor Readouts

May 20, 2025, 6:49 AM EDT - 5 months ago

Viking Therapeutics: Near-Term Catalysts And Competitor Readouts

Viking Therapeutics: Q1 Earnings Overview - Hard To Understand Wall Street's Pessimism

Apr 24, 2025, 8:58 AM EDT - 6 months ago

Viking Therapeutics: Q1 Earnings Overview - Hard To Understand Wall Street's Pessimism

Viking Therapeutics, Inc. (VKTX) Q1 2025 Earnings Call Transcript

Apr 23, 2025, 7:46 PM EDT - 6 months ago

Viking Therapeutics, Inc. (VKTX) Q1 2025 Earnings Call Transcript

Viking Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Apr 23, 2025, 4:05 PM EDT - 6 months ago

Viking Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Viking Therapeutics: A Lot More Compelling After The Meltdown - Initiating Cautious Buy (Rating Upgrade)

Apr 17, 2025, 9:30 AM EDT - 6 months ago

Viking Therapeutics: A Lot More Compelling After The Meltdown - Initiating Cautious Buy (Rating Upgrade)

Viking Therapeutics: Trading The Volatility Of The Weight Loss Drug Market

Apr 15, 2025, 4:21 PM EDT - 6 months ago

Viking Therapeutics: Trading The Volatility Of The Weight Loss Drug Market

Will Pfizer approach Viking Therapeutics with a buyout proposal?

Apr 15, 2025, 3:26 PM EDT - 6 months ago

Will Pfizer approach Viking Therapeutics with a buyout proposal?

MoneyGroupLLC
MoneyGroupLLC Oct. 25 at 6:27 AM
Enter: $VKTX Calls Strike Price: $35 Expiry Date: NOV 14 2025 Buy in Price: $2.70 - $4.60 Sell Price: $3.89 Profit : +44% (Turn every $1 into $1.44) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
DarkOrb
DarkOrb Oct. 25 at 3:40 AM
$VKTX Nothing is forcing BP to make a move. Their stock prices aren't suffering, VKTX stock price isn't running higher, etc. So they can wait for more trial data and more clarity on the obesity marketplace.
1 · Reply
JusKallmeGravy
JusKallmeGravy Oct. 25 at 2:12 AM
$VKTX We all have an opinion or two for what is best for Viking. The unfortunate truth is I pity the fool who gets it exactly right. The unfortunate soul who does will beat her, himself, or its self up for the rest of their life. For not becoming a billionaire if nothing else…not to mention the fact the SEC will be investigating the lucky winner guesser for the next 5 yrs . None the less - What we need is a ranking of the top 10 or 20 possibilities. We can adjust the rankings as things progress. Up or down …maybe Robinhood draft kings will let us take bets on the final 4 …or the eventual winner. I need some help tho…I’m full of ideas and only have two clumsy thumbs. Let’s get a form circulating At least the top ten …but I fear we could mis it completely if we don’t do a top 20 …any long shot can pull a rabbit out of … . Partnership or buy-out are the same value to keep it simple . We need a committee . I have done suggestions.
0 · Reply
saifnila2
saifnila2 Oct. 25 at 1:30 AM
$VKTX jpm actually lowered price to 75 from 80. Go figure. Absolutely nuts. No justification for price reduction, the analysts make this up from whatever they like. This has the potential for double digit billions revenue in a couple of years.
1 · Reply
biolover
biolover Oct. 25 at 1:26 AM
$VKTX the issue If BP understand phase 2 data and extrapolate to approval after all the dump predictions by novo and some analysts on CagriSema , MariTide , orforglipron….that were wrong. Probably as phase 3 trials progress and efficacy , safety leak .. more confidence grows. CEOs such as Bourla were more comfortable taking risk on a few billions. Here we talk about much more. Also Trump Lilly deal should settle uncertainty.
0 · Reply
lakeswim951
lakeswim951 Oct. 25 at 1:12 AM
$VKTX At this point, how can other big pharma companies not named Lilly and Nvo afford not to buy this company🤔
1 · Reply
biolover
biolover Oct. 25 at 12:52 AM
$VKTX clear correlation between SP rise from Sep 30 and the short coverage of 2 M. These shorted shares and daily massive trades by short acounts what is responsible for SP decline last 16 months. 2 M covered shares resulted in about 30% rise in SP ?
0 · Reply
RunGal
RunGal Oct. 25 at 12:46 AM
$VKTX Leerink buy rating…$118.
0 · Reply
FE123
FE123 Oct. 24 at 10:30 PM
$VKTX Short interest down over 2 Million because Deal is on the Way!!
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 24 at 10:14 PM
Enter: $VKTX NOV 14 2025 $35 CALLS Buy in Price: $2.76 - $2.95 Take Profit: $3.39 Stop Bleeding: $2.43 ROI Potential: 23% https://moneygroup.us/
0 · Reply
raticals
raticals Oct. 24 at 10:07 PM
$VKTX when the story is written on Viking(could be quick or long way off) it’ll be a fascinating read once we are able to learn. I’d imagine at least a dozen suitors, low ball offers, then massive offers. I’d bet a lot there are at least two standing offers at $100+ per share at present.
1 · Reply
biolover
biolover Oct. 24 at 8:28 PM
$VKTX short interest 2 M down. Not seen for a while. Probably slowly realizing will not make money on this ticker. Who is selling to them ?
2 · Reply
bavariaron
bavariaron Oct. 24 at 8:27 PM
$VKTX ** VK2735 Maintenance Study Hidden Value ** Informative piece with cogent analysis and unique insights. Courtesy of @Mufaso7 on X “The #VK2735 Maintenance Study intent which is find out if a monthly SubQ or Weekly Oral or Daily Oral can serve as an effective Weight Maintenance strategy using a reduce amount of API. This study is pioneering as this is a first of its kind study (no one has done a dedicated maintenance study in Obesity.“ https://x.com/mufaso7/status/1981771604121231568?s=46
0 · Reply
JIMMYDAMA
JIMMYDAMA Oct. 24 at 8:19 PM
$VKTX Thank You, Fantastic Article!!
0 · Reply
DG20
DG20 Oct. 24 at 8:12 PM
$VKTX Almost every CC, investor event and data drop has been used to tank the SP for the last 18 months. It was a good week…
1 · Reply
biolover
biolover Oct. 24 at 8:08 PM
$VKTX where interest down 2 M. That is interesting. As off Oct 14
1 · Reply
Duncan_
Duncan_ Oct. 24 at 8:06 PM
$VKTX
0 · Reply
Duncan_
Duncan_ Oct. 24 at 8:00 PM
$VKTX excellent link to article on x: Good read to learn about the latest on maintenance sq to oral. : https://x.com/Mufaso7/status/1981771604121231568
0 · Reply
wal5355
wal5355 Oct. 24 at 7:48 PM
$VKTX This viking is better than a season of Breaking Bad. I can not wait to see how this plays out.
0 · Reply
JIMMYDAMA
JIMMYDAMA Oct. 24 at 7:24 PM
$VKTX trying to Kill the $34 Calls over 1400 traded today Amazing how they spend so much time manipulating! Soon this will be over, I have a feeling real soon! GLTA Have a Great Weekend!
0 · Reply
LastResort
LastResort Oct. 24 at 7:19 PM
$VKTX This isn’t just a short squeeze setup. This is a potential macro trend reversal. It’s extremely rare to see a biotech compress like this with growing fundamentals, positive sentiment, and institutional coverage upgrades still active.
1 · Reply
jmartin795
jmartin795 Oct. 24 at 7:15 PM
$VKTX Nothing Burgers 🍔
0 · Reply